



Selected Phase I Clinical Trials  
(Updated May 2014)

Compound	Target	Sponsor	Location(s)	Scientific Rationale	Info Link	Contact
<a href="#">Pazopanib</a> with <a href="#">Vorinostat</a>	FGFR, VEGFR, PDGFR, HDAC	MD Anderson	Houston, TX	Strong	<a href="#">View</a>	Siqing Fu, MD,PHD 713-563-1930
<a href="#">Pazopanib</a> with <a href="#">Abexinostat</a> ( <a href="#">PCI-24781</a> )	FGFR, VEGFR, PDGFR, HDAC	UCSF	San Francisco, CA	Strong	<a href="#">View</a>	Pamela Munster, MD 415-885-7810 pmunster@medicine.ucsf.edu
<a href="#">MM-141</a>	IGF-1R, ERBB3	Merrimack	Boston, MA Marietta, GA Detroit, MI Villejuif, France	Solid	<a href="#">View</a>	Akos Czibere, MD, PhD 617-441-1000 Also view Info Link for details on each site
<a href="#">PLX7486</a>	TRKA, TRKB, TRKC, CSF-1R	Plexxikon	Phoenix, AZ Santa Monica, CA Charleston, SC (pending in Boston, MA, New York, NY, Baltimore, MD & San Francisco, CA)	Solid	<a href="#">View</a> (Part 2c)	David Karlin, MD 510-647-4100 dkarlin@plexxikon.com Sandy Tong, MD 510-647-4100 stong@plexxikon.com
<a href="#">Belinostat</a> with Chemotherapy	HDAC	National Cancer Institute	Bethesda, MD	Solid	<a href="#">View</a>	Robin R. Eisch, R.N. (301) 402-5958 eischar@mail.nih.gov Susan E Bates, M.D. (301) 402-0984 sebrates@helix.nih.gov

While the studies listed above may be of interest to any ACC patient, the studies below should be of particular interest to ACC patients whose [tumors have been profiled](#) and found to harbor genetic alterations in NOTCH pathway genes.

Selected Phase I Clinical Trials of NOTCH Inhibitors  
(Updated May 2014)

Compound	Target	Sponsor	Location(s)	Scientific Rationale	Info Link	Contact
<a href="#">OMP-52M51</a>	NOTCH1	OncoMed	San Francisco, CA Denver, CO Detroit, MI San Antonio, TX	Strong	<a href="#">View</a>	View Info Link for details on each site
<a href="#">BMS-906024</a>	NOTCH1-4	Bristol-Myers Squibb	Los Angeles, CA Detroit, MI Jackson, MS Houston, TX Parkville, Australia Toronto, Canada	Solid	<a href="#">View</a>	<a href="mailto:Clinical.Trials@bms.com">Clinical.Trials@bms.com</a>
<a href="#">BMS-906024</a> with Chemotherapy	NOTCH1-4	Bristol-Myers Squibb	Los Angeles, CA Brussels, Belgium Edmonton, Toronto & Ottawa, Canada	Solid	<a href="#">View</a>	<a href="mailto:Clinical.Trials@bms.com">Clinical.Trials@bms.com</a>